The one-stop shop concept is swiftly gaining traction in the contract manufacturing landscape. As pharma innovators increasingly integrate CMOs and CDMOs across their entire development process, many providers have started offering development and manufacturing services for both active pharmaceutical ingredients (APIs) and drug products under the same roof. Notably, digital transformation is the key to bringing down the increasing R&D costs in the sector, and CMOs and CDMOs are the centerpieces of it. Amid the ongoing disruptions like the pandemic-fueled digitalization sprint, the growing sustainability demands, and the third wave of biotech, partnerships with CMOs and CDMOs have become crucial for pharma and biopharma companies to stay competitive in the market with faster drug development, cost reduction, and swift market delivery. As a result, the pharmaceutical CMO/CDMO market valued at $183.62 billion last year is projected to reach $289.64 billion by 2027, at a CAGR of 7.29 percent.
To put the spotlight on such key developments, Pharma Tech Outlook highlights the vital technological advancements in the pharmaceuticals space and how CMOs and CDMOs leverage them to augment the development lifecycles of pharma and biopharma companies. The edition features thought leadership articles from Ozgur Akbulut, Director, Global Divestments and Contract Manufacturing Lead at Takeda, and Olga Minkov, Executive Director, Operations – Pharmacovigilance and Epi at Gilead Sciences, who throw light on the recent innovations in the pharmaceutical sector.
In this edition of Pharma Tech Outlook magazine, we bring you the story of some of the top CMOs/CDMOs that deliver the best outcomes for their clients, including ABL, Ascendia Pharmaceuticals, Aspen API, AstaTech, Center for Breakthrough Medicines, Goodwin Biotechnology, and TeleTec Electronics. We also highlight TCG GreenChem, a contract innovation company that provides CDMO services with a unique modus operandi in pharmaceutical R&D, and Andelyn Biosciences, a biopharmaceutical CDMO with more than two decades of expertise in pioneering viral vector and vaccine manufacturing.
Through the following pages, we aim to shine a light on the innovative trends and latest developments in the pharmaceutical space. We would like to know your thoughts.
